The pharmaceutical sector is comforting itself with a myth.

The narrative goes like this: “Access to physicians is declining, so we need more digital and more omnichannel.” It sounds logical. It feels modern. But it is fundamentally wrong.

Let’s clear up the confusion:

  • Digital is not a strategy. It is a channel.
  • Omnichannel is not a solution. It is just an organizational framework to structure those channels.

The real problem is much more uncomfortable. Doctors aren’t unreachable—we are just becoming irrelevant. Physicians don’t need more information; they are already drowning in it. What they lack isn’t access, but urgency. They have zero reason to listen, zero reason to carve out time, and zero reason to engage. Yet, our knee-jerk reflex never changes. When engagement drops, we simply blast more touchpoints. More emails. More webinars. More digital noise. But amplifying the same generic message doesn’t fix the outcome. It only amplifies the irrelevance.

This is pharma’s massive blind spot:

  • We optimize channels while ignoring content.
  • We invest in reach while losing sight of value.
  • We track activity and mistake it for impact.

No amount of frequency or technology can compensate for a lack of substance. Access must be earned. It’s time for a critical pivot. Stop asking: “How do we reach doctors?” Start asking: “Why on earth should they care to listen?”  The ultimate competitive advantage won’t belong to the company with the most channels, but to the one with the highest relevance. Are we ready to face the real challenge? Or will we keep hiding behind dashboards full of meaningless activity metrics?


P.S. A quick warning on the generative AI hype: feeding AI the same outdated, low-value input will only automate the nonsense at scale. (Though it might make your P&L look a bit prettier in the short term).